fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Lipase & amylase & protease

All products: Limited Use (codes 124, 125, 126, 225)

Creon Minimicrospheres 35 · DIN 02494639 · 35000 & 35700 & 2240 Units · DR capsule

Limited Use, Reason for Use code 124, 125, 126, 225 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 124, 125, 126, 225 required
Write on scriptone applicable Reason for Use code, 124 or 125 or 126 or 225 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 124, 125, 126, 225
Reason for Use code 124 Replacement therapy for pancreatic insufficiency secondary to pancreatic surgery (resection). Coverage limit: LU Authorization Period: Indefinite Reason for Use code 125 Replacement therapy for pancreatic insufficiency due to chronic pancreatitis. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 126 Replacement therapy for pancreatic insufficiency due to carcinoma of the pancreas. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 225 Replacement therapy for pancreatic insufficiency due to cystic fibrosis. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Creon Minimicrospheres 35 · DIN 02494639 Manufacturer: BGP Pharma ULC; listing date 2021-10-29 Health Canada: Marketed since 2021-01-26 · brand CREON MINIMICROSPHERES 35 · ATC A09AA02 MULTIENZYMES (LIPASE, PROTEASE ETC) · form Capsule (delayed-release) · route Oral · ingredients LIPASE 35000 UNIT, AMYLASE 35700 UNIT, PROTEASE 2240 UNIT · company Bgp pharma ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Creon Minimicrospheres 35: Formulary list price $0.97 per unit (the source does not state the unit; exact figure $0.9741). What the ministry pays, not the patient.

Ministry pays: $0.9741 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02494639)

Source record
DIN 02494639: Creon Minimicrospheres 35 Raw flags: sec12=Y, sec3=Y Item: 561600057; group id 657; item number 1640; lccId 00348; manufacturer id BGP Source form: DR Cap; strength: 35000 & 35700 & 2240 Units Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.9741; ministry $0.9741 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02494639 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98463
Shortage status: not checked (no credentials)

Other products in the same Health Canada class (A09AA): coverage varies; not interchangeable

  • Amylase + pancrelipase equivalent to lipase + protease (Cotazym): limited Use 124, 125, 126, limited Use 124, 125, 126, 225
Other drugs in the same formulary class (56:16 Digestants) and how they are covered

Matched class: 56:16 Digestants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. No displayed product is listed as a general benefit in this extract. Check its listing requirements below. 56:16 Digestants

PANCRELIPASE EQUIVALENT TO LIPASE & AMYLASE & PROTEASE

· 9 products · Limited Use, codes 124, 125, 126, 225 (6), Limited Use, codes 124, 125, 126 (3) · strengths: 10000 & 40000 & 35000 USP Units, 8000 & 30000 & 30000 USP Units, 20000 & 55000 & 55000 USP Units, 4000 & 12000 & 12000 USP Units, 10000 & 33200 & 37500 USP Units, 25000 & 74000 & 62500 USP Units, 5100 & 500 & 320 Units/100mg, 10440 & 56400 & 57100 USP Units, 16mg · Cap, Ent Microsph Cap, Ent Minimicrosph Cap, Gran - 100mg/Scoop, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 56:16
Full class listing Related classes: 56:04 Antacids and Adsorbents, 56:08 Antidiarrhea Agents, 56:12 Cathartics, 56:22 Antiemetics and Antinauseants, 56:40 Miscellaneous G.I. Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS CREON MINIMICROSPHERES® (pancreatin) is indicated in pediatric and adult patients for: • treatment of pancreatic exocrine insufficiency (PEI) attributed to cystic fibrosis, chronic pancreatitis, or any other medically defined pancreatic disease that might require pancreatic enzyme therapy including, but not limited to: • cystic fibrosis • chronic pancreatitis • pancreatic surgery • gastrectomy • pancreatic cancer • gastrointestinal bypass surgery (e.g. Billroth II gastroenterostomy) • ductal obstruction of the pancreas or common bile duct (e.g. from neoplasm) • Shwachman-Diamond Syndrome • status after an attack of acute pancreatitis and initiation of enteral or oral feeding 1.1 Pediatrics (≤ 18 years of age) CREON MINIMICROSPHERES® was shown to be effective in pediatric populations with PEI due to cystic fibrosis, independent of age and severity of the disease. The efficacy and safety observed during CREON MINIMICROSPHERES® treatment in these patients was similar to that in adult patients (See 8 ADVERSE REACTIONS and 14 CLINICAL TRIALS). 1.2 Geriatrics (≥ 6… https://pdf.hres.ca/dpd_pm/00076423.PDF PM date: November 25, 2013 Source product: CREON MINIMICROSPHERES 35; DIN 02494639; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.